Premium
POTENTIAL THERAPEUTIC ADVANTAGE FOR DUVELISIB IN MANTLE CELL LYMPHOMA: PI3Kδ AND OVEREXPRESSED PI3Kγ IN LYMPHOMA CELLS HAVE SPECIALIZED FUNCTIONAL ROLES
Author(s) -
Till K.J.,
Gallardo Zapata J.,
Marks T.,
Weaver D.T.,
Pachter J.A.,
Abdullah M.,
Kalakonda N.,
Pettitt A.R.,
Slupsky J.R.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.194_2631
Subject(s) - pi3k/akt/mtor pathway , mantle cell lymphoma , cancer research , lymphoma , medicine , idelalisib , pathology , biology , immunology , microbiology and biotechnology , ibrutinib , signal transduction , chronic lymphocytic leukemia , leukemia